Suzanne Oparil

TL;DR: Monitoring of albuminuria should be an integrated part of the management of hypertension if it is not decreased by the patient’s current antihypertensive and other treatment, and further intervention directed toward blood pressure control and other modifiable risks should be considered.

TL;DR: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind trial in 40,000 high-risk hypertensive patients, is designed to determine whether the combined incidence of fatal coronary heart disease (CHD) and nonfatal myocardial infarction differs between persons randomized to diuretic treatment and each of three alternative treatments.

TL;DR: This large prospective study of hypertensive patients with left ventricular hypertrophy found that increasing albuminuria is associated with a graded increase in risk, and any threshold identified would be much lower than the threshold traditionally defined in diabetic populations.

TL;DR: The ACCF/AHA Expert Consensus Document as discussed by the authors was developed as an expert consensus document by the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA), in collaboration with the American Academy of Neurology (AAN), AAN, the American Physicians Association (ACP), American Geriatrics Society (AGS), the American Society of Hypertension (ASH), the ASCN), ASCN, ASCP, American Society for Preventive Cardiology (ASPC), the Association of Black Cardiologists (ABC), and the European